



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Judith L. Treadway  
**Serial No.:** 09/767,633  
**Filed:** January 23, 2001  
**For:** METHODS OF TREATING  
DIABETIC CARDIOMYOPATHY USING  
GLYCOGEN PHOSPHORYLASE INHIBITORS

**Examiner:** Billy D. Chism  
**Art Unit:** 1654  
**Docket:** 16537 (PC10721A)  
**Dated:** August 5, 2004

**Confirmation No.:** 3428

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. International Patent Application No. WO 02/20530, published March 14, 2002;
2. International Patent Application No. WO 01/68092, published September 20, 2001;
3. International Patent Application No. WO 01/68055, published September 20, 2001;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450 on August 5, 2004.

Dated: August 5, 2004


Mark J. Cohen

4. European Patent Application Publication No. 1 088 824 A2; published April 4, 2001;
5. European Patent Application Publication No. 0 978 279 A1; published February 9, 2000; and
6. Martin, et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo", Proc. Natl. Acad. Sci., 95: 1776-1781 (1998)

The above-cited references were cited in a European Communication received from the European Patent Office in the corresponding European Patent Application No. 01 300 575.6-2123, a copy of which is enclosed. It is to be noted that the European Communication lists several additional publications therein; however, except for the publication listed hereinabove, the other publications have been made of record during the prosecution of the above-identified application.

Consideration of this Information Disclosure Statement is respectfully requested.

Respectfully submitted,



Mark J. Cohen

Registration No. 32,211

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
MJC:lf/rjl


Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(REV. 7-80) PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION****Atty. Docket No. (Optional)**

16537 (PC10721A)

**Application Number**

09/767,633

*(Use several sheets if necessary)***Applicant(s)**

Judith L. Treadway

**Filing Date**

January 23, 2001

**Group Art Unit**

1654

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)

**FOREIGN PATENT DOCUMENTS**

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	WO 02/20530	03/14/02	PCT			YES	NO
	WO 01/68092	09/20/01	PCT				
	WO 01/68055	09/20/01	PCT				
	1 088 824 A2	04/04/01	EPO				
	0 978 279 A1	02/09/00	EPO				

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Martin, et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo", <u>Proc. Natl. Acad. Sci.</u> , 95: 1776-1781 (1998)
	European Search Report, Application No. 01 300 575.6-2123, dated December 19, 2003

**EXAMINER****DATE CONSIDERED**

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.